Ozempic and other GLP-1s are reshaping narratives around weight loss and body image, yet their popularity prompts concerns about accessibility and societal body standards.
Many patients experience weight loss with GLP-1 agonists, but these 'miracle drugs' also highlight the intersections of health, fatphobia, and healthcare equity issues.
The rise of Ozempic is a reflection of our ongoing societal obsession with weight and body image, raising questions about the implications for children.
As GLP-1 agonists become mainstream yet controversial, parents may face dilemmas about promoting healthy body image while navigating their children’s expectations regarding weight loss.
Collection
[
|
...
]